Researchers have discovered a mechanism through which toxic protein clusters develop in the brain in Parkinson’s disease. It may be treatable with drugs approved for another disease.
In a paper published in the journal Neuron, the scientists describe how they discovered that increasing a fatty substance, or lipid, called glucosylceramide causes a buildup of toxic clusters of alpha-synuclein protein inside dopamine-producing brain cells.
The team also revealed that treatment with an already approved glucosylceramide synthase inhibitor — a drug that reduces production of the lipid — reduced the toxic protein clusters, which are a hallmark of Parkinson’s disease.
Working on a cure for a rare disease? Need Breakthrough Therapy designation, Fast Track Designation, RMAT Designation, FDA or EMA Orphan Designations? The BioPharma Global Regulatory Team can help – We are the #1 US based not-for-profit Global regulatory affairs firm with cost-effective, time-efficient solutions to chaperone your path through the regulatory affairs process. Contact us at http://www.biopharmaglobal.com/contact/ or by phone +1(202)660-1826